ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

by J. A. Kyte, A. Røssevold, R. S. Falk, B. Naume
Published 2020-06-01

ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer

by J. A. Kyte, N. K. Andresen, H. G. Russnes, S. Ø. Fretland, R. S. Falk, O. C. Lingjærde, B. Naume
Published 2020-07-01